Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1996 Feb 1;313(Pt 3):787–794. doi: 10.1042/bj3130787

Early proteolytic cleavage with loss of a C-terminal fragment underlies altered processing of the beta-galactosidase precursor in galactosialidosis.

Y Okamura-Oho 1, S Zhang 1, W Hilson 1, A Hinek 1, J W Callahan 1
PMCID: PMC1216979  PMID: 8611156

Abstract

Processing of human beta-galactosidase (beta-GAL) was studied in permanently transfected Chinese hamster ovary (CHO) cells and compared with that in normal cells and in cells from subjects with GM1-gangliosidosis, galactosialidosis and I-cell disease. Biosynthesis of beta-GAL in CHO cells results in the synthesis of an 88 kDa glycosylated and phosphorylated monomer precursor which is enzymically active and is secreted into the medium. Post-translational processing begins at the C-terminal end of the protein and gives rise to structurally related 67 and 64 kDa mature forms. These are subsequently degraded to give several inactive products of which a 50 kDa and a 18 kDa species are prominent. In normal fibroblasts only the 84 kDa precursor is readily detected inside cells, while the 88 kDa precursor is the only form secreted from cells in the presence of ammonium chloride. Processing of the precursor in normal fibroblasts results in the appearance of both the 67 and 64 kDa mature forms, which are also degraded to give 50 and 18 kDa products, as in transfected CHO cells. As affected controls, GM1-gangliosidosis cells showed a general loss of all forms of the enzyme, while in I-cell fibroblasts only the 84 kDa precursor and an 18 kDa degradation form were prominent. In galactosialidosis fibroblasts, taken from two different subjects, processing of beta-GAL was characterized by the respective appearance of intermediate 80 and 72 kDa enzymically inactive polypeptides, at levels lower than the normal amounts of the 67 and 64 kDa mature forms and higher than the normal amounts of degradation products, one of which is of 45 kDa and arises by endoproteolytic cleavage of the 80 kDa polypeptide. Incubation for up to 72 h in medium containing leupeptin, a potent inhibitor of thiol-dependent proteases, resulted in a significantly increased level of beta-GAL activity to near normal levels in fibroblasts from one galactosialidosis subject. Concordant with this, the abundance of the 84 kDa precursor was increased and the levels of the 80 kDa, 45 kDa and 18 kDa digestion products were diminished. However, in fibroblasts from the second galactosialidosis subject, the amount of the abnormal 72 kDa polypeptide was not influenced by leupeptin treatment. Leupeptin treatment did not increase enzymic activity levels in normal, GM1-gangliosidosis or I-cell disease fibroblasts, despite the fact that the production of the 50 kDa and 18 kDa degradation products was blocked in the presence of leupeptin. We concluded that in galactosialidosis the leupeptin-inhibitable proteolytic cleavage of a small fragment causes a conformational change of the precursor that precludes its further normal processing and results in its enzymic deficiency. This early abnormal trimming of beta-GAL is ascribable to a deficiency in the functional protective protein, the function of which is absolutely essential to render beta-GAL cryptic from at least two distinct and separate proteolytic attacks that together remove at least 12 kDa from the C-terminal end of the enzyme.

Full Text

The Full Text of this article is available as a PDF (429.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  2. D'Azzo A., Hoogeveen A., Reuser A. J., Robinson D., Galjaard H. Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4535–4539. doi: 10.1073/pnas.79.15.4535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Galjart N. J., Gillemans N., Harris A., van der Horst G. T., Verheijen F. W., Galjaard H., d'Azzo A. Expression of cDNA encoding the human "protective protein" associated with lysosomal beta-galactosidase and neuraminidase: homology to yeast proteases. Cell. 1988 Sep 9;54(6):755–764. doi: 10.1016/s0092-8674(88)90999-3. [DOI] [PubMed] [Google Scholar]
  4. Galjart N. J., Morreau H., Willemsen R., Gillemans N., Bonten E. J., d'Azzo A. Human lysosomal protective protein has cathepsin A-like activity distinct from its protective function. J Biol Chem. 1991 Aug 5;266(22):14754–14762. [PubMed] [Google Scholar]
  5. Hinek A., Rabinovitch M., Keeley F., Okamura-Oho Y., Callahan J. The 67-kD elastin/laminin-binding protein is related to an enzymatically inactive, alternatively spliced form of beta-galactosidase. J Clin Invest. 1993 Mar;91(3):1198–1205. doi: 10.1172/JCI116280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hoogeveen A. T., Reuser A. J., Kroos M., Galjaard H. GM1-gangliosidosis. Defective recognition site on beta-galactosidase precursor. J Biol Chem. 1986 May 5;261(13):5702–5704. [PubMed] [Google Scholar]
  7. Hubbes M., D'Agrosa R. M., Callahan J. W. Human placental beta-galactosidase. Characterization of the dimer and complex forms of the enzyme. Biochem J. 1992 Aug 1;285(Pt 3):827–831. doi: 10.1042/bj2850827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hurtley S. M., Helenius A. Protein oligomerization in the endoplasmic reticulum. Annu Rev Cell Biol. 1989;5:277–307. doi: 10.1146/annurev.cb.05.110189.001425. [DOI] [PubMed] [Google Scholar]
  9. Itoh K., Takiyama N., Kase R., Kondoh K., Sano A., Oshima A., Sakuraba H., Suzuki Y. Purification and characterization of human lysosomal protective protein expressed in stably transformed Chinese hamster ovary cells. J Biol Chem. 1993 Jan 15;268(2):1180–1186. [PubMed] [Google Scholar]
  10. Jackman H. L., Morris P. W., Deddish P. A., Skidgel R. A., Erdös E. G. Inactivation of endothelin I by deamidase (lysosomal protective protein). J Biol Chem. 1992 Feb 15;267(5):2872–2875. [PubMed] [Google Scholar]
  11. Jackman H. L., Tan F. L., Tamei H., Beurling-Harbury C., Li X. Y., Skidgel R. A., Erdös E. G. A peptidase in human platelets that deamidates tachykinins. Probable identity with the lysosomal "protective protein". J Biol Chem. 1990 Jul 5;265(19):11265–11272. [PubMed] [Google Scholar]
  12. Kase R., Itoh K., Takiyama N., Oshima A., Sakuraba H., Suzuki Y. Galactosialidosis: simultaneous deficiency of esterase, carboxy-terminal deamidase and acid carboxypeptidase activities. Biochem Biophys Res Commun. 1990 Nov 15;172(3):1175–1179. doi: 10.1016/0006-291x(90)91572-a. [DOI] [PubMed] [Google Scholar]
  13. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  14. Lodish H. F. Transport of secretory and membrane glycoproteins from the rough endoplasmic reticulum to the Golgi. A rate-limiting step in protein maturation and secretion. J Biol Chem. 1988 Feb 15;263(5):2107–2110. [PubMed] [Google Scholar]
  15. Nanba E., Tsuji A., Omura K., Suzuki Y. GM1-gangliosidosis: abnormalities in biosynthesis and early processing of beta-galactosidase in fibroblasts. Biochem Biophys Res Commun. 1988 Apr 29;152(2):794–800. doi: 10.1016/s0006-291x(88)80108-6. [DOI] [PubMed] [Google Scholar]
  16. Okamura-Oho Y., Zhang S., Callahan J. W. The biochemistry and clinical features of galactosialidosis. Biochim Biophys Acta. 1994 Feb 22;1225(3):244–254. doi: 10.1016/0925-4439(94)90002-7. [DOI] [PubMed] [Google Scholar]
  17. Pshezhetsky A. V., Elsliger M. A., Vinogradova M. V., Potier M. Human lysosomal beta-galactosidase-cathepsin A complex: definition of the beta-galactosidase-binding interface on cathepsin A. Biochemistry. 1995 Feb 28;34(8):2431–2440. doi: 10.1021/bi00008a005. [DOI] [PubMed] [Google Scholar]
  18. Pshezhetsky A. V., Levashov A. V., Wiederschain GYa Regulation of the GM1-galactosidase supramolecular structure and catalytic activity in vitro. Biochim Biophys Acta. 1992 Jul 31;1122(2):154–160. doi: 10.1016/0167-4838(92)90318-8. [DOI] [PubMed] [Google Scholar]
  19. Pshezhetsky A. V., Potier M. Direct affinity purification and supramolecular organization of human lysosomal cathepsin A. Arch Biochem Biophys. 1994 Aug 15;313(1):64–70. doi: 10.1006/abbi.1994.1359. [DOI] [PubMed] [Google Scholar]
  20. Pshezhetsky A. V., Potier M. Stoichiometry of the human lysosomal carboxypeptidase-beta-galactosidase complex. Biochem Biophys Res Commun. 1993 Aug 31;195(1):354–362. doi: 10.1006/bbrc.1993.2051. [DOI] [PubMed] [Google Scholar]
  21. Ren R., Mayer B. J., Cicchetti P., Baltimore D. Identification of a ten-amino acid proline-rich SH3 binding site. Science. 1993 Feb 19;259(5098):1157–1161. doi: 10.1126/science.8438166. [DOI] [PubMed] [Google Scholar]
  22. Takiyama N., Itoh K., Oshima A., Sakuraba H., Suzuki Y. Characterization of an anti-beta-galactosidase antibody recognizing a precursor but not a mature enzyme in solution. Biochem Biophys Res Commun. 1993 Jun 15;193(2):526–531. doi: 10.1006/bbrc.1993.1655. [DOI] [PubMed] [Google Scholar]
  23. Yamamoto Y., Hake C. A., Martin B. M., Kretz K. A., Ahern-Rindell A. J., Naylor S. L., Mudd M., O'Brien J. S. Isolation, characterization, and mapping of a human acid beta-galactosidase cDNA. DNA Cell Biol. 1990 Mar;9(2):119–127. doi: 10.1089/dna.1990.9.119. [DOI] [PubMed] [Google Scholar]
  24. Zhang S., McCarter J. D., Okamura-Oho Y., Yaghi F., Hinek A., Withers S. G., Callahan J. W. Kinetic mechanism and characterization of human beta-galactosidase precursor secreted by permanently transfected Chinese hamster ovary cells. Biochem J. 1994 Nov 15;304(Pt 1):281–288. doi: 10.1042/bj3040281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Zhou X. Y., Galjart N. J., Willemsen R., Gillemans N., Galjaard H., d'Azzo A. A mutation in a mild form of galactosialidosis impairs dimerization of the protective protein and renders it unstable. EMBO J. 1991 Dec;10(13):4041–4048. doi: 10.1002/j.1460-2075.1991.tb04980.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES